Evidence map›Paper›PMID 39162938›Full record

ArticleLa Radiologia medica2024

Budget impact analysis of introducing digital breast tomosynthesis in breast cancer screening in Italy.

Olivera Djuric, Silvia Deandrea, Paola Mantellini, Francesco Sardanelli, Francesco Venturelli, Stefania Montemezzi, Riccardo Vecchio, Lauro Bucchi, Carlo Senore, Livia Giordano and 22 more

Abstract read
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Olivera DjuricAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Silvia DeandreaPavia Health Protection Agency, Pavia, Italy.
Paola MantelliniISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy.
Francesco SardanelliIRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Francesco VenturelliAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Stefania MontemezziRadiology Unit - University Hospital of Verona, Verona, Italy.
Riccardo VecchioPavia Health Protection Agency, Pavia, Italy.
Lauro BucchiIRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l., Meldola, Forlì-Cesena, Italy.
Carlo SenoreAOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy.
Livia GiordanoAOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy.
Eugenio PaciItalian Cancer League, LILT, Florence, Italy.
Adriana BonifacinoFondazione IncontraDonna, Rome, Italy.
Massimo CalabreseBreast Unit. IRCCS-Policlinico San Martino, Genoa, Italy.
Francesca CaumoIstituto Oncologico Veneto IOV - IRCCS, Padua, Italy.
Flori DegrassiAssociazione Nazionale Donne Operate al Seno - ANDOS, Milan, Italy.
Priscilla Sassoli De' BianchiDepartment of Health, Emilia-Romagna Region Administration, Bologna, Italy.
Francesca BattistiISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy.
Marco ZappaISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy.
Pierpaolo PattaciniAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Cinzia CampariAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Andrea NitrosiAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Giovanni Di LeoIRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Alfonso FrigerioAOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy.
Veronica MagniIRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
Francesca FornasaBreast Unit ULSS9 Scaligera, Ospedale Fracastoro, San Bonifacio, Verona, Italy.
Giovanna RomanucciBreast Unit ULSS9 Scaligera, Ospedale Fracastoro, San Bonifacio, Verona, Italy.
Patrizia FaliniISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy.
Noemi AuzziISPRO - Istituto per lo Studio, la Prevenzione e la Rete Oncologica, Florence, Italy.
Paola ArmaroliAOU Città della Salute e della Scienza- CPO Piemonte Torino, Turin, Italy.
Paolo Giorgi RossiAzienda USL - IRCCS di Reggio Emilia, Reggio Emilia, Italy. paolo.giorgirossi@ausl.re.it.ORCID http://orcid.org/0000-0001-9703-2460
MAITA working group
Italian Breast Cancer Screening Guidelines working group

Funding

Ministero della Salute RF-2016-02363686
6 · The paper itself

Abstract

purposeThis study quantifies the impact on budget and cost per health benefit of implementing digital breast tomosynthesis (DBT) in place of digital mammography (DM) for breast cancer screening among asymptomatic women in Italy.

methodsA budget impact analysis and a cost consequence analysis were conducted using parameters from the MAITA project and literature. The study considered four scenarios for DBT implementation, i.e., DBT for all women, DBT for women aged 45-49 years, DBT based on breast density (BI-RADS C + D or D only), and compared these to the current DM screening. Healthcare provider's perspective was adopted, including screening, diagnosis, and cancer treatment costs.

resultsIntroducing DBT for all women would increase overall screening costs by 20%. Targeting DBT to women aged 45-49 years or with dense breasts would result in smaller cost increases (3.2% for age-based and 1.4-10.7% for density-based scenarios). The cost per avoided interval cancer was significantly higher when DBT was applied to all women compared to targeted approaches. The cost per gained early-detected cancer slightly increases in targeted approaches, while the assumptions on the clinical significance and overdiagnosis of cancers detected by DBT and not by DM have a strong impact.

conclusionsImplementing DBT as a primary breast cancer test in screening programs in Italy would lead to a substantial increase in costs. Tailoring DBT use to women aged 45-49 or with dense breasts could enhance the feasibility and sustainability of the intervention. Further research is needed to clarify the impact of DBT on overdiagnosis and the long-term outcomes.

Indexed as

Breast NeoplasmsBudgetsCost-Benefit AnalysisEarly Detection of CancerMammographyAgedFemaleHumansItalyMiddle AgedBreast neoplasmsBudget impact analysisCostDigital breast tomosynthesisDigital mammographyMass screening

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.